Načítá se...
Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
This post hoc analysis assessed the evidence behind common reimbursement practices by evaluating the relationship of body mass index (BMI) ranges (<30, 30–35 and >35 kg/m(2)) with treatment effects of exenatide twice daily among patients with type 2 diabetes. Patients received exenatide twice...
Uloženo v:
| Vydáno v: | Diabetes Obes Metab |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Blackwell Publishing Ltd
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5111732/ https://ncbi.nlm.nih.gov/pubmed/27027802 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12669 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|